Theravance Biopharma, Inc. Appoints Laurie Smaldone Alsup as Class I Member of the Board of Directors
February 15, 2018 at 04:30 pm EST
Share
On February 13, 2018, Laurie Smaldone Alsup, M.D. was appointed by the board of directors of Theravance Biopharma, Inc. to serve as a Class I member of the board of directors. The company’s board of directors has determined that Dr. Smaldone Alsup is independent within the meaning of the independent director standards of the Securities and Exchange Commission and Nasdaq Stock Market, Inc.
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
THERAVANCE BIOPHARMA, INC. 
